ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injection, 500 mL bags, ...
FDA Drug Recall #D-0147-2024 - Class II, November 29, 2023
Recall Summary
| Recall Number | D-0147-2024 |
| Classification | Class II - Moderate risk |
| Date Initiated | November 29, 2023 |
| Status | Completed |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | STAQ Pharma, Inc. |
| Location | Denver, CO |
| Product Type | Drugs |
| Quantity | 2616 bags |
Product Description
ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injection, 500 mL bags, Rx only, STAQ Pharma Inc. 14135 E 42nd Ave, Unit 50, Denver, Colorado 80239, NDC 73177-0109-26,
Reason for Recall
STAQ Pharma Inc. received consumer complaints related to leaking bags and other potential bag concerns. Upon investigation, they determine the source of the issue was with the bag manufacturer who released bags Lot # 134142-001A which had failed internal QC tests for leaks.
Distribution Pattern
Nationwide within the United States
Lot / Code Information
Lot#: 23109472A, Exp. date 03/10/2024; 23109473A, Exp. date 03/11/2024; 23109474A, Exp. date 03/13/2024; 23109491A, Exp. date 03/16/2024; 23109492A, Exp. date 03/19/2024; 23109501A, Exp. date 03/25/2024; 23109520A, Exp. date 04/10/2024; 23109521A, Exp. date 04/13/2024; 23109522A, Exp. date 04/03/2024.
Other Recalls from STAQ Pharma, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0024-2026 | Class III | Ketamine Hydrochloride, 50mg/5 mL (10mg/mL), In... | Oct 9, 2025 |
| D-0023-2026 | Class III | Hydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in ... | Oct 9, 2025 |
| D-0025-2026 | Class III | FentaNYL Citrate PF, 500mcg/50 mL (10mcg/mL) in... | Oct 9, 2025 |
| D-0633-2022 | Class I | HYDROmorphone HCl PF 10 mg/50 mL (0.2mg/mL) in ... | Feb 3, 2022 |
| D-0634-2022 | Class I | Morphine Sulfate PF 25 mg/25mL (1 mg/mL) in NaC... | Feb 3, 2022 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping, abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.